nodes	percent_of_prediction	percent_of_DWPC	metapath
Salbutamol—CYP3A4—type 2 diabetes mellitus	0.292	1	CbGaD
Salbutamol—ADRB1—Bromocriptine—type 2 diabetes mellitus	0.118	0.294	CbGbCtD
Salbutamol—CYP3A4—Linagliptin—type 2 diabetes mellitus	0.0432	0.108	CbGbCtD
Salbutamol—CYP3A4—Sitagliptin—type 2 diabetes mellitus	0.0385	0.0959	CbGbCtD
Salbutamol—CYP3A4—Glipizide—type 2 diabetes mellitus	0.0352	0.0877	CbGbCtD
Salbutamol—CYP3A4—Repaglinide—type 2 diabetes mellitus	0.0308	0.0766	CbGbCtD
Salbutamol—CYP3A4—Pioglitazone—type 2 diabetes mellitus	0.0278	0.0693	CbGbCtD
Salbutamol—CYP3A4—Nateglinide—type 2 diabetes mellitus	0.0211	0.0525	CbGbCtD
Salbutamol—CYP3A4—Orlistat—type 2 diabetes mellitus	0.0202	0.0504	CbGbCtD
Salbutamol—CYP3A4—Irbesartan—type 2 diabetes mellitus	0.0202	0.0504	CbGbCtD
Salbutamol—CYP3A4—Bromocriptine—type 2 diabetes mellitus	0.0191	0.0476	CbGbCtD
Salbutamol—CYP3A4—Glyburide—type 2 diabetes mellitus	0.0142	0.0355	CbGbCtD
Salbutamol—CYP3A4—Losartan—type 2 diabetes mellitus	0.013	0.0325	CbGbCtD
Salbutamol—Isoprenaline—PIK3R1—type 2 diabetes mellitus	0.00107	0.166	CrCbGaD
Salbutamol—Nadolol—ADRB3—type 2 diabetes mellitus	0.000801	0.124	CrCbGaD
Salbutamol—Clenbuterol—ADRB3—type 2 diabetes mellitus	0.000773	0.12	CrCbGaD
Salbutamol—Bupranolol—ADRB3—type 2 diabetes mellitus	0.000764	0.119	CrCbGaD
Salbutamol—Isoprenaline—ADRB3—type 2 diabetes mellitus	0.000386	0.0599	CrCbGaD
Salbutamol—Norepinephrine—ADRB3—type 2 diabetes mellitus	0.000358	0.0555	CrCbGaD
Salbutamol—Clenbuterol—TNF—type 2 diabetes mellitus	0.000332	0.0514	CrCbGaD
Salbutamol—Epinephrine—ADRB3—type 2 diabetes mellitus	0.000325	0.0504	CrCbGaD
Salbutamol—Levonordefrin—ADRA2A—type 2 diabetes mellitus	0.000273	0.0424	CrCbGaD
Salbutamol—Clenbuterol—CYP1A2—type 2 diabetes mellitus	0.000243	0.0377	CrCbGaD
Salbutamol—Phenylephrine—CYP1A2—type 2 diabetes mellitus	0.00022	0.0341	CrCbGaD
Salbutamol—Salmeterol—CYP3A4—type 2 diabetes mellitus	0.000171	0.0265	CrCbGaD
Salbutamol—Norepinephrine—ADRA2A—type 2 diabetes mellitus	0.000162	0.0251	CrCbGaD
Salbutamol—Epinephrine—ADRA2A—type 2 diabetes mellitus	0.000147	0.0228	CrCbGaD
Salbutamol—Epinephrine—TNF—type 2 diabetes mellitus	0.000139	0.0216	CrCbGaD
Salbutamol—Norepinephrine—CYP1A2—type 2 diabetes mellitus	0.000112	0.0175	CrCbGaD
Salbutamol—Musculoskeletal discomfort—Orlistat—type 2 diabetes mellitus	0.000106	0.00044	CcSEcCtD
Salbutamol—Paraesthesia—Valsartan—type 2 diabetes mellitus	0.000105	0.000439	CcSEcCtD
Salbutamol—Feeling abnormal—Gliclazide—type 2 diabetes mellitus	0.000105	0.000438	CcSEcCtD
Salbutamol—Chest pain—Irbesartan—type 2 diabetes mellitus	0.000105	0.000438	CcSEcCtD
Salbutamol—Arthralgia—Irbesartan—type 2 diabetes mellitus	0.000105	0.000438	CcSEcCtD
Salbutamol—Myalgia—Irbesartan—type 2 diabetes mellitus	0.000105	0.000438	CcSEcCtD
Salbutamol—Shock—Metformin—type 2 diabetes mellitus	0.000105	0.000438	CcSEcCtD
Salbutamol—Insomnia—Orlistat—type 2 diabetes mellitus	0.000105	0.000437	CcSEcCtD
Salbutamol—Malaise—Losartan—type 2 diabetes mellitus	0.000105	0.000437	CcSEcCtD
Salbutamol—Anxiety—Irbesartan—type 2 diabetes mellitus	0.000105	0.000436	CcSEcCtD
Salbutamol—Hypersensitivity—Glyburide—type 2 diabetes mellitus	0.000105	0.000436	CcSEcCtD
Salbutamol—Nervous system disorder—Metformin—type 2 diabetes mellitus	0.000105	0.000436	CcSEcCtD
Salbutamol—Dyspnoea—Valsartan—type 2 diabetes mellitus	0.000105	0.000436	CcSEcCtD
Salbutamol—Vertigo—Losartan—type 2 diabetes mellitus	0.000104	0.000435	CcSEcCtD
Salbutamol—Gastrointestinal pain—Gliclazide—type 2 diabetes mellitus	0.000104	0.000435	CcSEcCtD
Salbutamol—Somnolence—Valsartan—type 2 diabetes mellitus	0.000104	0.000434	CcSEcCtD
Salbutamol—Syncope—Losartan—type 2 diabetes mellitus	0.000104	0.000434	CcSEcCtD
Salbutamol—Paraesthesia—Orlistat—type 2 diabetes mellitus	0.000104	0.000433	CcSEcCtD
Salbutamol—Discomfort—Irbesartan—type 2 diabetes mellitus	0.000104	0.000433	CcSEcCtD
Salbutamol—Skin disorder—Metformin—type 2 diabetes mellitus	0.000104	0.000432	CcSEcCtD
Salbutamol—Immune system disorder—Ramipril—type 2 diabetes mellitus	0.000103	0.000431	CcSEcCtD
Salbutamol—Hyperhidrosis—Metformin—type 2 diabetes mellitus	0.000103	0.00043	CcSEcCtD
Salbutamol—Dyspepsia—Valsartan—type 2 diabetes mellitus	0.000103	0.00043	CcSEcCtD
Salbutamol—Mediastinal disorder—Ramipril—type 2 diabetes mellitus	0.000103	0.00043	CcSEcCtD
Salbutamol—Dizziness—Bromocriptine—type 2 diabetes mellitus	0.000103	0.000428	CcSEcCtD
Salbutamol—Dry mouth—Irbesartan—type 2 diabetes mellitus	0.000103	0.000428	CcSEcCtD
Salbutamol—Palpitations—Losartan—type 2 diabetes mellitus	0.000103	0.000428	CcSEcCtD
Salbutamol—Nausea—Glimepiride—type 2 diabetes mellitus	0.000102	0.000426	CcSEcCtD
Salbutamol—Arrhythmia—Ramipril—type 2 diabetes mellitus	0.000102	0.000426	CcSEcCtD
Salbutamol—Loss of consciousness—Losartan—type 2 diabetes mellitus	0.000102	0.000425	CcSEcCtD
Salbutamol—Nausea—Sitagliptin—type 2 diabetes mellitus	0.000102	0.000425	CcSEcCtD
Salbutamol—Epinephrine—CYP1A2—type 2 diabetes mellitus	0.000102	0.0158	CrCbGaD
Salbutamol—Dyspepsia—Orlistat—type 2 diabetes mellitus	0.000102	0.000425	CcSEcCtD
Salbutamol—Asthenia—Glyburide—type 2 diabetes mellitus	0.000102	0.000425	CcSEcCtD
Salbutamol—Decreased appetite—Valsartan—type 2 diabetes mellitus	0.000102	0.000425	CcSEcCtD
Salbutamol—Anorexia—Metformin—type 2 diabetes mellitus	0.000102	0.000424	CcSEcCtD
Salbutamol—Cough—Losartan—type 2 diabetes mellitus	0.000101	0.000422	CcSEcCtD
Salbutamol—Urticaria—Gliclazide—type 2 diabetes mellitus	0.000101	0.000422	CcSEcCtD
Salbutamol—Gastrointestinal disorder—Valsartan—type 2 diabetes mellitus	0.000101	0.000422	CcSEcCtD
Salbutamol—Fatigue—Valsartan—type 2 diabetes mellitus	0.000101	0.000421	CcSEcCtD
Salbutamol—Body temperature increased—Gliclazide—type 2 diabetes mellitus	0.000101	0.00042	CcSEcCtD
Salbutamol—Abdominal pain—Gliclazide—type 2 diabetes mellitus	0.000101	0.00042	CcSEcCtD
Salbutamol—Oedema—Irbesartan—type 2 diabetes mellitus	0.000101	0.00042	CcSEcCtD
Salbutamol—Anaphylactic shock—Irbesartan—type 2 diabetes mellitus	0.000101	0.00042	CcSEcCtD
Salbutamol—Decreased appetite—Orlistat—type 2 diabetes mellitus	0.000101	0.00042	CcSEcCtD
Salbutamol—Pruritus—Glyburide—type 2 diabetes mellitus	0.000101	0.000419	CcSEcCtD
Salbutamol—Mental disorder—Ramipril—type 2 diabetes mellitus	0.0001	0.000418	CcSEcCtD
Salbutamol—Constipation—Valsartan—type 2 diabetes mellitus	0.0001	0.000418	CcSEcCtD
Salbutamol—Infection—Irbesartan—type 2 diabetes mellitus	0.0001	0.000417	CcSEcCtD
Salbutamol—Gastrointestinal disorder—Orlistat—type 2 diabetes mellitus	0.0001	0.000417	CcSEcCtD
Salbutamol—Fatigue—Orlistat—type 2 diabetes mellitus	0.0001	0.000416	CcSEcCtD
Salbutamol—Hypotension—Metformin—type 2 diabetes mellitus	9.98e-05	0.000416	CcSEcCtD
Salbutamol—Malnutrition—Ramipril—type 2 diabetes mellitus	9.97e-05	0.000415	CcSEcCtD
Salbutamol—Shock—Irbesartan—type 2 diabetes mellitus	9.92e-05	0.000413	CcSEcCtD
Salbutamol—Pain—Orlistat—type 2 diabetes mellitus	9.91e-05	0.000413	CcSEcCtD
Salbutamol—Chest pain—Losartan—type 2 diabetes mellitus	9.9e-05	0.000412	CcSEcCtD
Salbutamol—Arthralgia—Losartan—type 2 diabetes mellitus	9.9e-05	0.000412	CcSEcCtD
Salbutamol—Myalgia—Losartan—type 2 diabetes mellitus	9.9e-05	0.000412	CcSEcCtD
Salbutamol—Vomiting—Bromocriptine—type 2 diabetes mellitus	9.89e-05	0.000412	CcSEcCtD
Salbutamol—Nervous system disorder—Irbesartan—type 2 diabetes mellitus	9.89e-05	0.000412	CcSEcCtD
Salbutamol—Anxiety—Losartan—type 2 diabetes mellitus	9.86e-05	0.000411	CcSEcCtD
Salbutamol—Tachycardia—Irbesartan—type 2 diabetes mellitus	9.84e-05	0.00041	CcSEcCtD
Salbutamol—Rash—Bromocriptine—type 2 diabetes mellitus	9.81e-05	0.000408	CcSEcCtD
Salbutamol—Dermatitis—Bromocriptine—type 2 diabetes mellitus	9.8e-05	0.000408	CcSEcCtD
Salbutamol—Skin disorder—Irbesartan—type 2 diabetes mellitus	9.79e-05	0.000408	CcSEcCtD
Salbutamol—Tension—Ramipril—type 2 diabetes mellitus	9.78e-05	0.000407	CcSEcCtD
Salbutamol—Discomfort—Losartan—type 2 diabetes mellitus	9.78e-05	0.000407	CcSEcCtD
Salbutamol—Dysgeusia—Ramipril—type 2 diabetes mellitus	9.76e-05	0.000406	CcSEcCtD
Salbutamol—Hyperhidrosis—Irbesartan—type 2 diabetes mellitus	9.75e-05	0.000406	CcSEcCtD
Salbutamol—Headache—Bromocriptine—type 2 diabetes mellitus	9.75e-05	0.000406	CcSEcCtD
Salbutamol—Musculoskeletal discomfort—Metformin—type 2 diabetes mellitus	9.73e-05	0.000405	CcSEcCtD
Salbutamol—Diarrhoea—Glyburide—type 2 diabetes mellitus	9.73e-05	0.000405	CcSEcCtD
Salbutamol—Nervousness—Ramipril—type 2 diabetes mellitus	9.68e-05	0.000403	CcSEcCtD
Salbutamol—Dry mouth—Losartan—type 2 diabetes mellitus	9.68e-05	0.000403	CcSEcCtD
Salbutamol—Anorexia—Irbesartan—type 2 diabetes mellitus	9.61e-05	0.0004	CcSEcCtD
Salbutamol—Gastrointestinal pain—Valsartan—type 2 diabetes mellitus	9.59e-05	0.000399	CcSEcCtD
Salbutamol—Paraesthesia—Metformin—type 2 diabetes mellitus	9.59e-05	0.000399	CcSEcCtD
Salbutamol—Muscle spasms—Ramipril—type 2 diabetes mellitus	9.58e-05	0.000399	CcSEcCtD
Salbutamol—Feeling abnormal—Orlistat—type 2 diabetes mellitus	9.55e-05	0.000398	CcSEcCtD
Salbutamol—Dyspnoea—Metformin—type 2 diabetes mellitus	9.53e-05	0.000397	CcSEcCtD
Salbutamol—Somnolence—Metformin—type 2 diabetes mellitus	9.5e-05	0.000395	CcSEcCtD
Salbutamol—Oedema—Losartan—type 2 diabetes mellitus	9.49e-05	0.000395	CcSEcCtD
Salbutamol—Anaphylactic shock—Losartan—type 2 diabetes mellitus	9.49e-05	0.000395	CcSEcCtD
Salbutamol—Gastrointestinal pain—Orlistat—type 2 diabetes mellitus	9.48e-05	0.000395	CcSEcCtD
Salbutamol—Infection—Losartan—type 2 diabetes mellitus	9.43e-05	0.000392	CcSEcCtD
Salbutamol—Hypotension—Irbesartan—type 2 diabetes mellitus	9.42e-05	0.000392	CcSEcCtD
Salbutamol—Hypersensitivity—Gliclazide—type 2 diabetes mellitus	9.41e-05	0.000392	CcSEcCtD
Salbutamol—Dyspepsia—Metformin—type 2 diabetes mellitus	9.4e-05	0.000392	CcSEcCtD
Salbutamol—Tremor—Ramipril—type 2 diabetes mellitus	9.34e-05	0.000389	CcSEcCtD
Salbutamol—Shock—Losartan—type 2 diabetes mellitus	9.34e-05	0.000389	CcSEcCtD
Salbutamol—Urticaria—Valsartan—type 2 diabetes mellitus	9.32e-05	0.000388	CcSEcCtD
Salbutamol—Nervous system disorder—Losartan—type 2 diabetes mellitus	9.31e-05	0.000387	CcSEcCtD
Salbutamol—Decreased appetite—Metformin—type 2 diabetes mellitus	9.29e-05	0.000387	CcSEcCtD
Salbutamol—Abdominal pain—Valsartan—type 2 diabetes mellitus	9.27e-05	0.000386	CcSEcCtD
Salbutamol—Tachycardia—Losartan—type 2 diabetes mellitus	9.26e-05	0.000386	CcSEcCtD
Salbutamol—Ill-defined disorder—Ramipril—type 2 diabetes mellitus	9.25e-05	0.000385	CcSEcCtD
Salbutamol—Nausea—Bromocriptine—type 2 diabetes mellitus	9.24e-05	0.000385	CcSEcCtD
Salbutamol—Gastrointestinal disorder—Metformin—type 2 diabetes mellitus	9.22e-05	0.000384	CcSEcCtD
Salbutamol—Fatigue—Metformin—type 2 diabetes mellitus	9.21e-05	0.000384	CcSEcCtD
Salbutamol—Urticaria—Orlistat—type 2 diabetes mellitus	9.21e-05	0.000383	CcSEcCtD
Salbutamol—Musculoskeletal discomfort—Irbesartan—type 2 diabetes mellitus	9.19e-05	0.000382	CcSEcCtD
Salbutamol—Hyperhidrosis—Losartan—type 2 diabetes mellitus	9.17e-05	0.000382	CcSEcCtD
Salbutamol—Body temperature increased—Orlistat—type 2 diabetes mellitus	9.16e-05	0.000382	CcSEcCtD
Salbutamol—Abdominal pain—Orlistat—type 2 diabetes mellitus	9.16e-05	0.000382	CcSEcCtD
Salbutamol—Asthenia—Gliclazide—type 2 diabetes mellitus	9.16e-05	0.000381	CcSEcCtD
Salbutamol—Agitation—Ramipril—type 2 diabetes mellitus	9.16e-05	0.000381	CcSEcCtD
Salbutamol—Constipation—Metformin—type 2 diabetes mellitus	9.14e-05	0.00038	CcSEcCtD
Salbutamol—Angioedema—Ramipril—type 2 diabetes mellitus	9.11e-05	0.000379	CcSEcCtD
Salbutamol—Paraesthesia—Irbesartan—type 2 diabetes mellitus	9.05e-05	0.000377	CcSEcCtD
Salbutamol—Anorexia—Losartan—type 2 diabetes mellitus	9.04e-05	0.000377	CcSEcCtD
Salbutamol—Vomiting—Glyburide—type 2 diabetes mellitus	9.04e-05	0.000376	CcSEcCtD
Salbutamol—Pruritus—Gliclazide—type 2 diabetes mellitus	9.03e-05	0.000376	CcSEcCtD
Salbutamol—Malaise—Ramipril—type 2 diabetes mellitus	8.99e-05	0.000374	CcSEcCtD
Salbutamol—Dyspnoea—Irbesartan—type 2 diabetes mellitus	8.99e-05	0.000374	CcSEcCtD
Salbutamol—Rash—Glyburide—type 2 diabetes mellitus	8.97e-05	0.000373	CcSEcCtD
Salbutamol—Somnolence—Irbesartan—type 2 diabetes mellitus	8.96e-05	0.000373	CcSEcCtD
Salbutamol—Dermatitis—Glyburide—type 2 diabetes mellitus	8.96e-05	0.000373	CcSEcCtD
Salbutamol—Vertigo—Ramipril—type 2 diabetes mellitus	8.96e-05	0.000373	CcSEcCtD
Salbutamol—Syncope—Ramipril—type 2 diabetes mellitus	8.94e-05	0.000372	CcSEcCtD
Salbutamol—Headache—Glyburide—type 2 diabetes mellitus	8.91e-05	0.000371	CcSEcCtD
Salbutamol—Dyspepsia—Irbesartan—type 2 diabetes mellitus	8.88e-05	0.00037	CcSEcCtD
Salbutamol—Hypotension—Losartan—type 2 diabetes mellitus	8.87e-05	0.000369	CcSEcCtD
Salbutamol—Palpitations—Ramipril—type 2 diabetes mellitus	8.81e-05	0.000367	CcSEcCtD
Salbutamol—Feeling abnormal—Metformin—type 2 diabetes mellitus	8.8e-05	0.000367	CcSEcCtD
Salbutamol—Decreased appetite—Irbesartan—type 2 diabetes mellitus	8.76e-05	0.000365	CcSEcCtD
Salbutamol—Loss of consciousness—Ramipril—type 2 diabetes mellitus	8.76e-05	0.000365	CcSEcCtD
Salbutamol—Diarrhoea—Gliclazide—type 2 diabetes mellitus	8.74e-05	0.000364	CcSEcCtD
Salbutamol—Gastrointestinal pain—Metformin—type 2 diabetes mellitus	8.74e-05	0.000364	CcSEcCtD
Salbutamol—Gastrointestinal disorder—Irbesartan—type 2 diabetes mellitus	8.7e-05	0.000362	CcSEcCtD
Salbutamol—Cough—Ramipril—type 2 diabetes mellitus	8.7e-05	0.000362	CcSEcCtD
Salbutamol—Fatigue—Irbesartan—type 2 diabetes mellitus	8.69e-05	0.000362	CcSEcCtD
Salbutamol—Musculoskeletal discomfort—Losartan—type 2 diabetes mellitus	8.64e-05	0.00036	CcSEcCtD
Salbutamol—Hypersensitivity—Valsartan—type 2 diabetes mellitus	8.64e-05	0.00036	CcSEcCtD
Salbutamol—Pain—Irbesartan—type 2 diabetes mellitus	8.62e-05	0.000359	CcSEcCtD
Salbutamol—Constipation—Irbesartan—type 2 diabetes mellitus	8.62e-05	0.000359	CcSEcCtD
Salbutamol—Insomnia—Losartan—type 2 diabetes mellitus	8.58e-05	0.000357	CcSEcCtD
Salbutamol—Hypersensitivity—Orlistat—type 2 diabetes mellitus	8.54e-05	0.000356	CcSEcCtD
Salbutamol—Paraesthesia—Losartan—type 2 diabetes mellitus	8.52e-05	0.000355	CcSEcCtD
Salbutamol—Urticaria—Metformin—type 2 diabetes mellitus	8.49e-05	0.000353	CcSEcCtD
Salbutamol—Myalgia—Ramipril—type 2 diabetes mellitus	8.49e-05	0.000353	CcSEcCtD
Salbutamol—Chest pain—Ramipril—type 2 diabetes mellitus	8.49e-05	0.000353	CcSEcCtD
Salbutamol—Arthralgia—Ramipril—type 2 diabetes mellitus	8.49e-05	0.000353	CcSEcCtD
Salbutamol—Dyspnoea—Losartan—type 2 diabetes mellitus	8.46e-05	0.000352	CcSEcCtD
Salbutamol—Anxiety—Ramipril—type 2 diabetes mellitus	8.46e-05	0.000352	CcSEcCtD
Salbutamol—Nausea—Glyburide—type 2 diabetes mellitus	8.45e-05	0.000352	CcSEcCtD
Salbutamol—Abdominal pain—Metformin—type 2 diabetes mellitus	8.45e-05	0.000352	CcSEcCtD
Salbutamol—Dizziness—Gliclazide—type 2 diabetes mellitus	8.44e-05	0.000352	CcSEcCtD
Salbutamol—Somnolence—Losartan—type 2 diabetes mellitus	8.44e-05	0.000351	CcSEcCtD
Salbutamol—Asthenia—Valsartan—type 2 diabetes mellitus	8.42e-05	0.00035	CcSEcCtD
Salbutamol—Discomfort—Ramipril—type 2 diabetes mellitus	8.39e-05	0.000349	CcSEcCtD
Salbutamol—Dyspepsia—Losartan—type 2 diabetes mellitus	8.35e-05	0.000348	CcSEcCtD
Salbutamol—Asthenia—Orlistat—type 2 diabetes mellitus	8.32e-05	0.000346	CcSEcCtD
Salbutamol—Feeling abnormal—Irbesartan—type 2 diabetes mellitus	8.31e-05	0.000346	CcSEcCtD
Salbutamol—Pruritus—Valsartan—type 2 diabetes mellitus	8.3e-05	0.000346	CcSEcCtD
Salbutamol—Dry mouth—Ramipril—type 2 diabetes mellitus	8.3e-05	0.000346	CcSEcCtD
Salbutamol—Decreased appetite—Losartan—type 2 diabetes mellitus	8.25e-05	0.000343	CcSEcCtD
Salbutamol—Gastrointestinal pain—Irbesartan—type 2 diabetes mellitus	8.24e-05	0.000343	CcSEcCtD
Salbutamol—Pruritus—Orlistat—type 2 diabetes mellitus	8.2e-05	0.000342	CcSEcCtD
Salbutamol—Fatigue—Losartan—type 2 diabetes mellitus	8.18e-05	0.000341	CcSEcCtD
Salbutamol—Anaphylactic shock—Ramipril—type 2 diabetes mellitus	8.14e-05	0.000339	CcSEcCtD
Salbutamol—Oedema—Ramipril—type 2 diabetes mellitus	8.14e-05	0.000339	CcSEcCtD
Salbutamol—Vomiting—Gliclazide—type 2 diabetes mellitus	8.12e-05	0.000338	CcSEcCtD
Salbutamol—Constipation—Losartan—type 2 diabetes mellitus	8.11e-05	0.000338	CcSEcCtD
Salbutamol—Pain—Losartan—type 2 diabetes mellitus	8.11e-05	0.000338	CcSEcCtD
Salbutamol—Rash—Gliclazide—type 2 diabetes mellitus	8.05e-05	0.000335	CcSEcCtD
Salbutamol—Dermatitis—Gliclazide—type 2 diabetes mellitus	8.04e-05	0.000335	CcSEcCtD
Salbutamol—Diarrhoea—Valsartan—type 2 diabetes mellitus	8.03e-05	0.000334	CcSEcCtD
Salbutamol—Urticaria—Irbesartan—type 2 diabetes mellitus	8.01e-05	0.000334	CcSEcCtD
Salbutamol—Shock—Ramipril—type 2 diabetes mellitus	8e-05	0.000333	CcSEcCtD
Salbutamol—Headache—Gliclazide—type 2 diabetes mellitus	8e-05	0.000333	CcSEcCtD
Salbutamol—Nervous system disorder—Ramipril—type 2 diabetes mellitus	7.98e-05	0.000332	CcSEcCtD
Salbutamol—Body temperature increased—Irbesartan—type 2 diabetes mellitus	7.97e-05	0.000332	CcSEcCtD
Salbutamol—Abdominal pain—Irbesartan—type 2 diabetes mellitus	7.97e-05	0.000332	CcSEcCtD
Salbutamol—Tachycardia—Ramipril—type 2 diabetes mellitus	7.94e-05	0.000331	CcSEcCtD
Salbutamol—Diarrhoea—Orlistat—type 2 diabetes mellitus	7.93e-05	0.00033	CcSEcCtD
Salbutamol—Skin disorder—Ramipril—type 2 diabetes mellitus	7.9e-05	0.000329	CcSEcCtD
Salbutamol—Hyperhidrosis—Ramipril—type 2 diabetes mellitus	7.87e-05	0.000327	CcSEcCtD
Salbutamol—Feeling abnormal—Losartan—type 2 diabetes mellitus	7.82e-05	0.000326	CcSEcCtD
Salbutamol—Gastrointestinal pain—Losartan—type 2 diabetes mellitus	7.76e-05	0.000323	CcSEcCtD
Salbutamol—Dizziness—Valsartan—type 2 diabetes mellitus	7.76e-05	0.000323	CcSEcCtD
Salbutamol—Anorexia—Ramipril—type 2 diabetes mellitus	7.76e-05	0.000323	CcSEcCtD
Salbutamol—Dizziness—Orlistat—type 2 diabetes mellitus	7.67e-05	0.000319	CcSEcCtD
Salbutamol—Asthenia—Metformin—type 2 diabetes mellitus	7.67e-05	0.000319	CcSEcCtD
Salbutamol—Hypotension—Ramipril—type 2 diabetes mellitus	7.6e-05	0.000317	CcSEcCtD
Salbutamol—Nausea—Gliclazide—type 2 diabetes mellitus	7.59e-05	0.000316	CcSEcCtD
Salbutamol—Pruritus—Metformin—type 2 diabetes mellitus	7.56e-05	0.000315	CcSEcCtD
Salbutamol—Urticaria—Losartan—type 2 diabetes mellitus	7.54e-05	0.000314	CcSEcCtD
Salbutamol—Body temperature increased—Losartan—type 2 diabetes mellitus	7.5e-05	0.000312	CcSEcCtD
Salbutamol—Abdominal pain—Losartan—type 2 diabetes mellitus	7.5e-05	0.000312	CcSEcCtD
Salbutamol—Vomiting—Valsartan—type 2 diabetes mellitus	7.46e-05	0.000311	CcSEcCtD
Salbutamol—Hypersensitivity—Irbesartan—type 2 diabetes mellitus	7.43e-05	0.000309	CcSEcCtD
Salbutamol—Musculoskeletal discomfort—Ramipril—type 2 diabetes mellitus	7.41e-05	0.000309	CcSEcCtD
Salbutamol—Rash—Valsartan—type 2 diabetes mellitus	7.4e-05	0.000308	CcSEcCtD
Salbutamol—Dermatitis—Valsartan—type 2 diabetes mellitus	7.39e-05	0.000308	CcSEcCtD
Salbutamol—Vomiting—Orlistat—type 2 diabetes mellitus	7.37e-05	0.000307	CcSEcCtD
Salbutamol—Insomnia—Ramipril—type 2 diabetes mellitus	7.36e-05	0.000306	CcSEcCtD
Salbutamol—Headache—Valsartan—type 2 diabetes mellitus	7.35e-05	0.000306	CcSEcCtD
Salbutamol—Diarrhoea—Metformin—type 2 diabetes mellitus	7.31e-05	0.000304	CcSEcCtD
Salbutamol—Rash—Orlistat—type 2 diabetes mellitus	7.31e-05	0.000304	CcSEcCtD
Salbutamol—Paraesthesia—Ramipril—type 2 diabetes mellitus	7.31e-05	0.000304	CcSEcCtD
Salbutamol—Dermatitis—Orlistat—type 2 diabetes mellitus	7.3e-05	0.000304	CcSEcCtD
Salbutamol—Headache—Orlistat—type 2 diabetes mellitus	7.26e-05	0.000302	CcSEcCtD
Salbutamol—Dyspnoea—Ramipril—type 2 diabetes mellitus	7.25e-05	0.000302	CcSEcCtD
Salbutamol—Asthenia—Irbesartan—type 2 diabetes mellitus	7.23e-05	0.000301	CcSEcCtD
Salbutamol—Somnolence—Ramipril—type 2 diabetes mellitus	7.23e-05	0.000301	CcSEcCtD
Salbutamol—Dyspepsia—Ramipril—type 2 diabetes mellitus	7.16e-05	0.000298	CcSEcCtD
Salbutamol—Pruritus—Irbesartan—type 2 diabetes mellitus	7.13e-05	0.000297	CcSEcCtD
Salbutamol—Decreased appetite—Ramipril—type 2 diabetes mellitus	7.07e-05	0.000294	CcSEcCtD
Salbutamol—Dizziness—Metformin—type 2 diabetes mellitus	7.07e-05	0.000294	CcSEcCtD
Salbutamol—Gastrointestinal disorder—Ramipril—type 2 diabetes mellitus	7.02e-05	0.000292	CcSEcCtD
Salbutamol—Fatigue—Ramipril—type 2 diabetes mellitus	7.01e-05	0.000292	CcSEcCtD
Salbutamol—Hypersensitivity—Losartan—type 2 diabetes mellitus	6.99e-05	0.000291	CcSEcCtD
Salbutamol—Nausea—Valsartan—type 2 diabetes mellitus	6.97e-05	0.00029	CcSEcCtD
Salbutamol—Constipation—Ramipril—type 2 diabetes mellitus	6.96e-05	0.00029	CcSEcCtD
Salbutamol—Diarrhoea—Irbesartan—type 2 diabetes mellitus	6.9e-05	0.000287	CcSEcCtD
Salbutamol—Nausea—Orlistat—type 2 diabetes mellitus	6.89e-05	0.000287	CcSEcCtD
Salbutamol—Asthenia—Losartan—type 2 diabetes mellitus	6.81e-05	0.000283	CcSEcCtD
Salbutamol—Vomiting—Metformin—type 2 diabetes mellitus	6.79e-05	0.000283	CcSEcCtD
Salbutamol—Epinephrine—CYP3A4—type 2 diabetes mellitus	6.76e-05	0.0105	CrCbGaD
Salbutamol—Rash—Metformin—type 2 diabetes mellitus	6.74e-05	0.00028	CcSEcCtD
Salbutamol—Dermatitis—Metformin—type 2 diabetes mellitus	6.73e-05	0.00028	CcSEcCtD
Salbutamol—Pruritus—Losartan—type 2 diabetes mellitus	6.71e-05	0.00028	CcSEcCtD
Salbutamol—Feeling abnormal—Ramipril—type 2 diabetes mellitus	6.7e-05	0.000279	CcSEcCtD
Salbutamol—Headache—Metformin—type 2 diabetes mellitus	6.69e-05	0.000279	CcSEcCtD
Salbutamol—Dizziness—Irbesartan—type 2 diabetes mellitus	6.67e-05	0.000278	CcSEcCtD
Salbutamol—Gastrointestinal pain—Ramipril—type 2 diabetes mellitus	6.65e-05	0.000277	CcSEcCtD
Salbutamol—Diarrhoea—Losartan—type 2 diabetes mellitus	6.49e-05	0.00027	CcSEcCtD
Salbutamol—Urticaria—Ramipril—type 2 diabetes mellitus	6.46e-05	0.000269	CcSEcCtD
Salbutamol—Abdominal pain—Ramipril—type 2 diabetes mellitus	6.43e-05	0.000268	CcSEcCtD
Salbutamol—Body temperature increased—Ramipril—type 2 diabetes mellitus	6.43e-05	0.000268	CcSEcCtD
Salbutamol—Vomiting—Irbesartan—type 2 diabetes mellitus	6.41e-05	0.000267	CcSEcCtD
Salbutamol—Rash—Irbesartan—type 2 diabetes mellitus	6.36e-05	0.000265	CcSEcCtD
Salbutamol—Dermatitis—Irbesartan—type 2 diabetes mellitus	6.35e-05	0.000264	CcSEcCtD
Salbutamol—Nausea—Metformin—type 2 diabetes mellitus	6.35e-05	0.000264	CcSEcCtD
Salbutamol—Headache—Irbesartan—type 2 diabetes mellitus	6.32e-05	0.000263	CcSEcCtD
Salbutamol—Dizziness—Losartan—type 2 diabetes mellitus	6.27e-05	0.000261	CcSEcCtD
Salbutamol—Vomiting—Losartan—type 2 diabetes mellitus	6.03e-05	0.000251	CcSEcCtD
Salbutamol—Hypersensitivity—Ramipril—type 2 diabetes mellitus	5.99e-05	0.00025	CcSEcCtD
Salbutamol—Nausea—Irbesartan—type 2 diabetes mellitus	5.99e-05	0.000249	CcSEcCtD
Salbutamol—Rash—Losartan—type 2 diabetes mellitus	5.98e-05	0.000249	CcSEcCtD
Salbutamol—Dermatitis—Losartan—type 2 diabetes mellitus	5.98e-05	0.000249	CcSEcCtD
Salbutamol—Headache—Losartan—type 2 diabetes mellitus	5.94e-05	0.000248	CcSEcCtD
Salbutamol—Asthenia—Ramipril—type 2 diabetes mellitus	5.84e-05	0.000243	CcSEcCtD
Salbutamol—Pruritus—Ramipril—type 2 diabetes mellitus	5.76e-05	0.00024	CcSEcCtD
Salbutamol—Nausea—Losartan—type 2 diabetes mellitus	5.64e-05	0.000235	CcSEcCtD
Salbutamol—Diarrhoea—Ramipril—type 2 diabetes mellitus	5.57e-05	0.000232	CcSEcCtD
Salbutamol—Dizziness—Ramipril—type 2 diabetes mellitus	5.38e-05	0.000224	CcSEcCtD
Salbutamol—Vomiting—Ramipril—type 2 diabetes mellitus	5.17e-05	0.000215	CcSEcCtD
Salbutamol—Rash—Ramipril—type 2 diabetes mellitus	5.13e-05	0.000214	CcSEcCtD
Salbutamol—Dermatitis—Ramipril—type 2 diabetes mellitus	5.13e-05	0.000213	CcSEcCtD
Salbutamol—Headache—Ramipril—type 2 diabetes mellitus	5.1e-05	0.000212	CcSEcCtD
Salbutamol—Nausea—Ramipril—type 2 diabetes mellitus	4.83e-05	0.000201	CcSEcCtD
Salbutamol—ADRB1—GPCR downstream signaling—ADCY5—type 2 diabetes mellitus	2.37e-05	0.000394	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—GNB3—type 2 diabetes mellitus	2.36e-05	0.000393	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—CCKAR—type 2 diabetes mellitus	2.35e-05	0.000391	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—GLP1R—type 2 diabetes mellitus	2.33e-05	0.000388	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—RBP4—type 2 diabetes mellitus	2.33e-05	0.000388	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—AVP—type 2 diabetes mellitus	2.33e-05	0.000388	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—MMP3—type 2 diabetes mellitus	2.33e-05	0.000388	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—ADCY5—type 2 diabetes mellitus	2.32e-05	0.000386	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—CCKAR—type 2 diabetes mellitus	2.3e-05	0.000382	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—EDN1—type 2 diabetes mellitus	2.26e-05	0.000377	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—BHMT—type 2 diabetes mellitus	2.26e-05	0.000376	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—CCR5—type 2 diabetes mellitus	2.23e-05	0.000371	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—EDN1—type 2 diabetes mellitus	2.22e-05	0.000369	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—CCR5—type 2 diabetes mellitus	2.18e-05	0.000363	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—C3—type 2 diabetes mellitus	2.18e-05	0.000363	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—ADCY5—type 2 diabetes mellitus	2.15e-05	0.000358	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—C3—type 2 diabetes mellitus	2.13e-05	0.000355	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—ATP2A2—type 2 diabetes mellitus	2.13e-05	0.000354	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—IAPP—type 2 diabetes mellitus	2.11e-05	0.000352	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—ADCY5—type 2 diabetes mellitus	2.1e-05	0.00035	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—INSR—type 2 diabetes mellitus	2.1e-05	0.00035	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—ATP2A2—type 2 diabetes mellitus	2.08e-05	0.000346	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—AGT—type 2 diabetes mellitus	2.07e-05	0.000344	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—IAPP—type 2 diabetes mellitus	2.07e-05	0.000344	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—TRPC6—type 2 diabetes mellitus	2.06e-05	0.000343	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—PPP2CA—type 2 diabetes mellitus	2.06e-05	0.000343	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—INSR—type 2 diabetes mellitus	2.06e-05	0.000342	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—AGTR2—type 2 diabetes mellitus	2.05e-05	0.000341	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—AGT—type 2 diabetes mellitus	2.02e-05	0.000337	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—CCR5—type 2 diabetes mellitus	2.02e-05	0.000337	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—TRPC6—type 2 diabetes mellitus	2.02e-05	0.000336	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—PPP2CA—type 2 diabetes mellitus	2.02e-05	0.000336	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—AGTR2—type 2 diabetes mellitus	2.01e-05	0.000334	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—CCR5—type 2 diabetes mellitus	1.98e-05	0.00033	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—C3—type 2 diabetes mellitus	1.98e-05	0.000329	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—PTGDS—type 2 diabetes mellitus	1.97e-05	0.000329	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—AANAT—type 2 diabetes mellitus	1.97e-05	0.000329	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—EDNRB—type 2 diabetes mellitus	1.96e-05	0.000327	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—C3—type 2 diabetes mellitus	1.94e-05	0.000322	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—EDNRB—type 2 diabetes mellitus	1.92e-05	0.00032	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—PRKCB—type 2 diabetes mellitus	1.91e-05	0.000318	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—PSMD6—type 2 diabetes mellitus	1.91e-05	0.000317	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—HTR2C—type 2 diabetes mellitus	1.91e-05	0.000317	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—AGT—type 2 diabetes mellitus	1.88e-05	0.000313	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—CDO1—type 2 diabetes mellitus	1.87e-05	0.000311	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—GPD2—type 2 diabetes mellitus	1.87e-05	0.000311	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—PRKCB—type 2 diabetes mellitus	1.87e-05	0.000311	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—PSMD6—type 2 diabetes mellitus	1.87e-05	0.000311	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—HTR2C—type 2 diabetes mellitus	1.87e-05	0.000311	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—EDNRA—type 2 diabetes mellitus	1.86e-05	0.000309	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—CALM1—type 2 diabetes mellitus	1.85e-05	0.000308	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—CYBA—type 2 diabetes mellitus	1.85e-05	0.000307	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—AGT—type 2 diabetes mellitus	1.84e-05	0.000306	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—ADRA2A—type 2 diabetes mellitus	1.82e-05	0.000302	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—EDNRA—type 2 diabetes mellitus	1.82e-05	0.000302	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—PLAT—type 2 diabetes mellitus	1.81e-05	0.000301	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—GHRL—type 2 diabetes mellitus	1.81e-05	0.000301	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—CALM1—type 2 diabetes mellitus	1.81e-05	0.000301	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—CYBA—type 2 diabetes mellitus	1.81e-05	0.000301	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—CALCA—type 2 diabetes mellitus	1.79e-05	0.000297	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—AK1—type 2 diabetes mellitus	1.79e-05	0.000297	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—ADRA2A—type 2 diabetes mellitus	1.78e-05	0.000296	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—GHRL—type 2 diabetes mellitus	1.77e-05	0.000294	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—PLAT—type 2 diabetes mellitus	1.77e-05	0.000294	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—CALCA—type 2 diabetes mellitus	1.75e-05	0.000291	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—PRKCB—type 2 diabetes mellitus	1.74e-05	0.000289	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—PRKCB—type 2 diabetes mellitus	1.7e-05	0.000283	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—TCF7L2—type 2 diabetes mellitus	1.68e-05	0.00028	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—AKT2—type 2 diabetes mellitus	1.67e-05	0.000279	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—GCG—type 2 diabetes mellitus	1.65e-05	0.000275	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—PTPN1—type 2 diabetes mellitus	1.65e-05	0.000275	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—SLC5A4—type 2 diabetes mellitus	1.65e-05	0.000274	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—MAT1A—type 2 diabetes mellitus	1.65e-05	0.000274	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—TCF7L2—type 2 diabetes mellitus	1.65e-05	0.000274	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—AKT2—type 2 diabetes mellitus	1.64e-05	0.000273	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—RASGRP1—type 2 diabetes mellitus	1.63e-05	0.000271	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—NOTCH2—type 2 diabetes mellitus	1.62e-05	0.00027	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—GCG—type 2 diabetes mellitus	1.62e-05	0.000269	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—PTPN1—type 2 diabetes mellitus	1.62e-05	0.000269	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—RASGRP1—type 2 diabetes mellitus	1.59e-05	0.000265	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—ENPP1—type 2 diabetes mellitus	1.59e-05	0.000265	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—PPP1R3C—type 2 diabetes mellitus	1.59e-05	0.000265	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—ND1—type 2 diabetes mellitus	1.59e-05	0.000265	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—G6PC—type 2 diabetes mellitus	1.59e-05	0.000265	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—HBA2—type 2 diabetes mellitus	1.59e-05	0.000265	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—NOTCH2—type 2 diabetes mellitus	1.59e-05	0.000264	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—CCL2—type 2 diabetes mellitus	1.55e-05	0.000258	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—GCGR—type 2 diabetes mellitus	1.54e-05	0.000256	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—AKT2—type 2 diabetes mellitus	1.52e-05	0.000253	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—PIK3R1—type 2 diabetes mellitus	1.52e-05	0.000253	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—CCL2—type 2 diabetes mellitus	1.51e-05	0.000252	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—AKT2—type 2 diabetes mellitus	1.49e-05	0.000248	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—PIK3R1—type 2 diabetes mellitus	1.49e-05	0.000247	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—OXCT1—type 2 diabetes mellitus	1.46e-05	0.000242	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—CYTB—type 2 diabetes mellitus	1.46e-05	0.000242	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—TGFBR2—type 2 diabetes mellitus	1.44e-05	0.000239	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—GNB3—type 2 diabetes mellitus	1.43e-05	0.000237	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—SRD5A1—type 2 diabetes mellitus	1.42e-05	0.000236	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—TGFBR2—type 2 diabetes mellitus	1.41e-05	0.000234	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—AVP—type 2 diabetes mellitus	1.41e-05	0.000234	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—MMP3—type 2 diabetes mellitus	1.41e-05	0.000234	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—IGF2—type 2 diabetes mellitus	1.4e-05	0.000233	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—GNB3—type 2 diabetes mellitus	1.39e-05	0.000232	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	1.39e-05	0.000232	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—PIK3R1—type 2 diabetes mellitus	1.38e-05	0.00023	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—AVP—type 2 diabetes mellitus	1.38e-05	0.000229	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—MMP3—type 2 diabetes mellitus	1.38e-05	0.000229	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—IGF2—type 2 diabetes mellitus	1.37e-05	0.000228	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	1.36e-05	0.000227	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—APOB—type 2 diabetes mellitus	1.36e-05	0.000226	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—IGF1R—type 2 diabetes mellitus	1.35e-05	0.000225	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—STAR—type 2 diabetes mellitus	1.35e-05	0.000225	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—ACACA—type 2 diabetes mellitus	1.35e-05	0.000225	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—HSD17B3—type 2 diabetes mellitus	1.35e-05	0.000225	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—PIK3R1—type 2 diabetes mellitus	1.35e-05	0.000225	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—EDN1—type 2 diabetes mellitus	1.34e-05	0.000223	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—APOB—type 2 diabetes mellitus	1.33e-05	0.000221	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—IGF1R—type 2 diabetes mellitus	1.32e-05	0.00022	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—EDN1—type 2 diabetes mellitus	1.31e-05	0.000218	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—LPL—type 2 diabetes mellitus	1.3e-05	0.000216	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—ABCC8—type 2 diabetes mellitus	1.3e-05	0.000216	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—CBS—type 2 diabetes mellitus	1.3e-05	0.000216	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—ADCY5—type 2 diabetes mellitus	1.27e-05	0.000211	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—LPL—type 2 diabetes mellitus	1.27e-05	0.000211	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—SLC5A2—type 2 diabetes mellitus	1.25e-05	0.000208	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—COX2—type 2 diabetes mellitus	1.25e-05	0.000208	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—ADCY5—type 2 diabetes mellitus	1.24e-05	0.000207	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—NCOA6—type 2 diabetes mellitus	1.23e-05	0.000204	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	1.22e-05	0.000203	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—HSD11B1—type 2 diabetes mellitus	1.21e-05	0.000201	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—UCP3—type 2 diabetes mellitus	1.21e-05	0.000201	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—UCP2—type 2 diabetes mellitus	1.21e-05	0.000201	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—CCR5—type 2 diabetes mellitus	1.2e-05	0.000199	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	1.19e-05	0.000198	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—CCR5—type 2 diabetes mellitus	1.17e-05	0.000195	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—C3—type 2 diabetes mellitus	1.17e-05	0.000194	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—C3—type 2 diabetes mellitus	1.14e-05	0.00019	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—PCK1—type 2 diabetes mellitus	1.13e-05	0.000189	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—HIF1A—type 2 diabetes mellitus	1.11e-05	0.000185	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—IRS2—type 2 diabetes mellitus	1.11e-05	0.000185	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—AGT—type 2 diabetes mellitus	1.11e-05	0.000185	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—CALM1—type 2 diabetes mellitus	1.09e-05	0.000182	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—HIF1A—type 2 diabetes mellitus	1.09e-05	0.000181	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—LEP—type 2 diabetes mellitus	1.09e-05	0.000181	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—APOE—type 2 diabetes mellitus	1.09e-05	0.000181	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—IRS2—type 2 diabetes mellitus	1.09e-05	0.000181	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—AGT—type 2 diabetes mellitus	1.09e-05	0.000181	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—APOA1—type 2 diabetes mellitus	1.08e-05	0.000179	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—CALM1—type 2 diabetes mellitus	1.07e-05	0.000178	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—APOE—type 2 diabetes mellitus	1.06e-05	0.000177	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—LEP—type 2 diabetes mellitus	1.06e-05	0.000177	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—HK1—type 2 diabetes mellitus	1.06e-05	0.000177	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—APOA1—type 2 diabetes mellitus	1.05e-05	0.000175	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—PRKCB—type 2 diabetes mellitus	1.03e-05	0.000171	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—LPA—type 2 diabetes mellitus	1.03e-05	0.000171	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—GCKR—type 2 diabetes mellitus	1.03e-05	0.000171	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—HSD3B2—type 2 diabetes mellitus	1.03e-05	0.000171	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—KCNJ11—type 2 diabetes mellitus	1.03e-05	0.000171	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—PRKCB—type 2 diabetes mellitus	1e-05	0.000167	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—ALDOB—type 2 diabetes mellitus	9.83e-06	0.000164	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—IRS1—type 2 diabetes mellitus	9.7e-06	0.000162	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—IRS1—type 2 diabetes mellitus	9.49e-06	0.000158	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—INS—type 2 diabetes mellitus	9.29e-06	0.000155	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—CCL2—type 2 diabetes mellitus	9.14e-06	0.000152	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—GLP1R—type 2 diabetes mellitus	9.14e-06	0.000152	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—INS—type 2 diabetes mellitus	9.09e-06	0.000151	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—IGF1—type 2 diabetes mellitus	8.99e-06	0.00015	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—AKT2—type 2 diabetes mellitus	8.98e-06	0.000149	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—EGFR—type 2 diabetes mellitus	8.95e-06	0.000149	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—CCL2—type 2 diabetes mellitus	8.95e-06	0.000149	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—IGF1—type 2 diabetes mellitus	8.79e-06	0.000146	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—AKT2—type 2 diabetes mellitus	8.79e-06	0.000146	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—EGFR—type 2 diabetes mellitus	8.75e-06	0.000146	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	8.54e-06	0.000142	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—SLC2A2—type 2 diabetes mellitus	8.53e-06	0.000142	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—CPT1A—type 2 diabetes mellitus	8.36e-06	0.000139	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—MTR—type 2 diabetes mellitus	8.36e-06	0.000139	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	8.35e-06	0.000139	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—NAMPT—type 2 diabetes mellitus	8.2e-06	0.000136	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	8.15e-06	0.000136	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—NOS3—type 2 diabetes mellitus	8.15e-06	0.000136	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—GCK—type 2 diabetes mellitus	8.15e-06	0.000136	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—HBA1—type 2 diabetes mellitus	8.15e-06	0.000136	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—LIPC—type 2 diabetes mellitus	8.15e-06	0.000136	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—CYP11A1—type 2 diabetes mellitus	8.1e-06	0.000135	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—NOS3—type 2 diabetes mellitus	7.97e-06	0.000133	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	7.97e-06	0.000133	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—SLC9A1—type 2 diabetes mellitus	7.95e-06	0.000132	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—CETP—type 2 diabetes mellitus	7.86e-06	0.000131	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—RELA—type 2 diabetes mellitus	7.67e-06	0.000128	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—RELA—type 2 diabetes mellitus	7.5e-06	0.000125	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—SREBF1—type 2 diabetes mellitus	7.31e-06	0.000122	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—PSMD6—type 2 diabetes mellitus	7.31e-06	0.000122	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—SNAP25—type 2 diabetes mellitus	7.31e-06	0.000122	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—CTGF—type 2 diabetes mellitus	7.17e-06	0.000119	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—HMGCR—type 2 diabetes mellitus	7.11e-06	0.000118	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	6.98e-06	0.000116	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—ADRA2A—type 2 diabetes mellitus	6.96e-06	0.000116	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—CASP3—type 2 diabetes mellitus	6.92e-06	0.000115	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—IL6—type 2 diabetes mellitus	6.87e-06	0.000114	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	6.83e-06	0.000114	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—CASP3—type 2 diabetes mellitus	6.77e-06	0.000113	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—IL6—type 2 diabetes mellitus	6.72e-06	0.000112	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—CYP2E1—type 2 diabetes mellitus	6.68e-06	0.000111	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—CYP1A2—type 2 diabetes mellitus	6.61e-06	0.00011	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—SLC2A1—type 2 diabetes mellitus	6.61e-06	0.00011	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—MMP9—type 2 diabetes mellitus	6.54e-06	0.000109	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—NFKB1—type 2 diabetes mellitus	6.47e-06	0.000108	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—MMP9—type 2 diabetes mellitus	6.4e-06	0.000106	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—AKT1—type 2 diabetes mellitus	6.34e-06	0.000106	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—GCG—type 2 diabetes mellitus	6.34e-06	0.000105	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—SLC2A4—type 2 diabetes mellitus	6.34e-06	0.000105	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—NFKB1—type 2 diabetes mellitus	6.33e-06	0.000105	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—AKT1—type 2 diabetes mellitus	6.2e-06	0.000103	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—SRC—type 2 diabetes mellitus	6.03e-06	0.0001	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—SRC—type 2 diabetes mellitus	5.9e-06	9.81e-05	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—VEGFA—type 2 diabetes mellitus	5.87e-06	9.77e-05	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—VEGFA—type 2 diabetes mellitus	5.74e-06	9.56e-05	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—PPARGC1A—type 2 diabetes mellitus	5.46e-06	9.09e-05	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—GNB3—type 2 diabetes mellitus	5.46e-06	9.09e-05	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—HMOX1—type 2 diabetes mellitus	5.44e-06	9.05e-05	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—TGFB1—type 2 diabetes mellitus	5.39e-06	8.97e-05	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—CAT—type 2 diabetes mellitus	5.36e-06	8.92e-05	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—EGFR—type 2 diabetes mellitus	5.28e-06	8.79e-05	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—TGFB1—type 2 diabetes mellitus	5.27e-06	8.77e-05	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—APOB—type 2 diabetes mellitus	5.21e-06	8.66e-05	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—EGFR—type 2 diabetes mellitus	5.17e-06	8.6e-05	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—GSTM1—type 2 diabetes mellitus	5.06e-06	8.43e-05	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—LPL—type 2 diabetes mellitus	4.97e-06	8.27e-05	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—ADCY5—type 2 diabetes mellitus	4.87e-06	8.1e-05	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—GPX1—type 2 diabetes mellitus	4.85e-06	8.07e-05	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—CD36—type 2 diabetes mellitus	4.72e-06	7.86e-05	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—PPP2CA—type 2 diabetes mellitus	4.66e-06	7.76e-05	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—MTHFR—type 2 diabetes mellitus	4.48e-06	7.45e-05	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—PPARA—type 2 diabetes mellitus	4.39e-06	7.31e-05	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—AGT—type 2 diabetes mellitus	4.25e-06	7.08e-05	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—CALM1—type 2 diabetes mellitus	4.18e-06	6.96e-05	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—APOE—type 2 diabetes mellitus	4.17e-06	6.93e-05	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—APOA1—type 2 diabetes mellitus	4.12e-06	6.86e-05	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—IL6—type 2 diabetes mellitus	4.06e-06	6.76e-05	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—IL6—type 2 diabetes mellitus	3.97e-06	6.61e-05	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—AKT1—type 2 diabetes mellitus	3.75e-06	6.23e-05	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—AKT1—type 2 diabetes mellitus	3.66e-06	6.1e-05	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—PPARG—type 2 diabetes mellitus	3.63e-06	6.04e-05	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—INS—type 2 diabetes mellitus	3.56e-06	5.92e-05	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—ALB—type 2 diabetes mellitus	3.26e-06	5.43e-05	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—PIK3R1—type 2 diabetes mellitus	3.12e-06	5.2e-05	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—NOS3—type 2 diabetes mellitus	3.12e-06	5.2e-05	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—PTGS2—type 2 diabetes mellitus	2.86e-06	4.75e-05	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—AKT1—type 2 diabetes mellitus	1.44e-06	2.39e-05	CbGpPWpGaD
